See more : Hypoport SE (HYQ.DE) Income Statement Analysis – Financial Results
Complete financial analysis of ZyVersa Therapeutics, Inc. (ZVSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZyVersa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shuang Yun Holdings Limited (1706.HK) Income Statement Analysis – Financial Results
- Baosheng Media Group Holdings Limited (BAOS) Income Statement Analysis – Financial Results
- Tenpo Innovation CO.,LTD. (3484.T) Income Statement Analysis – Financial Results
- Lipum AB (publ) (LIPUM.ST) Income Statement Analysis – Financial Results
- Groupe Gorgé SA (GOE.PA) Income Statement Analysis – Financial Results
ZyVersa Therapeutics, Inc. (ZVSA)
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.40K | 10.40K | 10.40K | 10.40K |
| Gross Profit | -10.40K | -10.40K | -10.40K | -10.40K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.21M | 5.41M | 2.12M | 6.47M |
| General & Administrative | 11.21B | 7.61M | 5.58M | 5.36M |
| Selling & Marketing | -11.20B | 0.00 | 0.00 | 0.00 |
| SG&A | 11.20M | 7.61M | 5.58M | 5.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 13.01M | 7.70M | 11.83M |
| Cost & Expenses | 14.42M | 13.01M | 7.70M | 11.83M |
| Interest Income | 0.00 | 427.54 | 821.37 | 516.45 |
| Interest Expense | -457.00K | 427.54K | 821.37K | 516.45K |
| Depreciation & Amortization | 10.40K | 10.40K | 10.40K | 10.40K |
| EBITDA | -107.74M | -11.67M | -7.25M | -12.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.42M | -13.01M | -7.70M | -11.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -93.33M | -2.37M | -379.79K | -850.11K |
| Income Before Tax | -107.75M | -14.05M | -8.08M | -12.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.46M | 745.05M | 821.37K | 516.45K |
| Net Income | -98.30M | -759.10M | -8.91M | -13.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.09K | -930.25 | -173.66 | -272.45 |
| EPS Diluted | -1.09K | -930.25 | -173.66 | -272.45 |
| Weighted Avg Shares Out | 97.50K | 25.95K | 46.55K | 46.55K |
| Weighted Avg Shares Out (Dil) | 97.50K | 25.95K | 46.55K | 46.55K |
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on elevated ASC levels in older adults (>60 years) who were cognitively normal at baseline but demonstrated cognitive decline one year...
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that obesity and its related metabolic complications has...
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
Publication showed that IC 100 suppressed retinal microglia activation by interfering with ASC speck formation, attenuating retinal inflammation, abnormal retinal vascularization, and retinal thinning, and it led to restored retinal function. Retinopathy of Prematurity (ROP), affecting very low birth weight...
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of obesity...
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024. GLP toxicology studies for Inflammasome ASC Inhibitor IC 100...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease
NLRP1 & pyrin govern inflammation in Alzheimer's Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide. The published data show that inhibiting the NLRP3 inflammasome...
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024. Inflammasome ASC Inhibitor IC 100 preclinical program nearing completion, with planned Investigational New Drug (IND) submission Q4-2024, and...
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
Phase 2a trial is on track to begin in the first half of 2024. Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic kidney disease and...
Source: https://incomestatements.info
Category: Stock Reports
What were ZyVersa’s Q3 2024 net losses?
Net losses were approximately $2.4 million for the three months ended September 30, 2024, with an improvement of approximately $0.5 million or 17.3% compared to a net loss of approximately $2.9 million for the three months ended September 30, 2023.